65.37

3.73% 2.35

Ptc Therapeutics Inc (PTCT)

Overview News Price History Option Chain Financials Why PTCT Down? Discussions Forecast

Ptc Therapeutics Inc stock is traded at $65.37, with a volume of 2.72M. It is up +3.73% in the last 24 hours and up +17.68% over the past month. PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

Previous Close:

$63.02

Open:

$63.71

24h Volume:

2.72M

Relative Volume:

2.17

Market Cap:

$5.19B

Revenue:

$900.66M

Net Income/Loss:

$-453.20M

P/E Ratio:

-11.01

EPS:

-5.94

Net Cash Flow:

$-274.19M

1W Performance:

+10.82%

1M Performance:

+17.68%

6M Performance:

+39.89%

1Y Performance:

+84.82%

1-Day Range:

$63.29

$67.40

1-Week Range:

$58.90

$67.40

52-Week Range:

$34.57

$67.40

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Name

Ptc Therapeutics Inc

Sector

Healthcare (1145)

Industry

Biotechnology (640)

Phone

(908) 222-7000

Address

500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ

Employee

939

Twitter

@PTCBio

Next Earnings Date

2024-11-07

Latest SEC Filings

PTCT's Discussions on Twitter

Compare PTCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTCT Ptc Therapeutics Inc	65.37	5.01B	900.66M	-453.20M	-274.19M	-5.94
VRTX Vertex Pharmaceuticals Inc	403.30	104.83B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	600.00	63.59B	14.21B	4.46B	3.56B	39.69
ALNY Alnylam Pharmaceuticals Inc	456.35	60.43B	2.46B	-319.09M	-52.09M	-2.4669
ARGX Argen X Se Adr	800.00	48.45B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	343.87	37.91B	4.56B	-176.77M	225.30M	-1.7177

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-25	Initiated	Truist	Buy
May-09-25	Upgrade	BofA Securities	Neutral → Buy
May-07-25	Upgrade	Citigroup	Sell → Neutral
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral
Mar-07-25	Initiated	Scotiabank	Sector Perform
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform
Aug-26-24	Resumed	UBS	Buy
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-08-23	Initiated	Wells Fargo	Overweight
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform
Oct-27-23	Downgrade	Citigroup	Neutral → Sell
Oct-06-23	Downgrade	Truist	Buy → Hold
Sep-18-23	Downgrade	Citigroup	Buy → Neutral
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform
Dec-14-22	Initiated	Goldman	Sell
Sep-12-22	Initiated	Jefferies	Buy
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
Sep-01-22	Initiated	Citigroup	Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Oct-18-21	Downgrade	BofA Securities	Neutral → Underperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-29-21	Upgrade	RBC Capital Mkts	Underperform → Sector Perform
Feb-12-21	Downgrade	BofA Securities	Buy → Neutral
Jan-05-21	Upgrade	Citigroup	Neutral → Buy
Nov-30-20	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
Oct-30-20	Downgrade	Citigroup	Buy → Neutral
Oct-28-20	Initiated	UBS	Neutral
Oct-07-20	Upgrade	JP Morgan	Neutral → Overweight
Aug-25-20	Initiated	Raymond James	Outperform
Apr-09-20	Upgrade	Citigroup	Neutral → Buy
Feb-20-20	Downgrade	Citigroup	Buy → Neutral
Feb-20-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-12-19	Initiated	SunTrust	Buy
May-13-19	Upgrade	BofA/Merrill	Neutral → Buy
Apr-11-19	Initiated	Bernstein	Outperform
Oct-03-18	Upgrade	BofA/Merrill	Underperform → Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Jun-18-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Apr-04-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-29-18	Resumed	RBC Capital Mkts	Sector Perform
Nov-16-17	Upgrade	JP Morgan	Underweight → Neutral
Oct-26-17	Downgrade	BofA/Merrill	Neutral → Underperform
Oct-09-17	Downgrade	JP Morgan	Neutral → Underweight

View All

Ptc Therapeutics Inc Stock (PTCT) Latest News

Oct 03, 2025

Will PTC Therapeutics Inc. rebound enough to break evenVolume Spike & Precise Buy Zone Identification - newser.com

Oct 03, 2025

Real time breakdown of PTC Therapeutics Inc. stock performanceBull Run & Free Safe Entry Trade Signal Reports - newser.com

Oct 03, 2025

Why PTC Therapeutics Inc. (BH3) stock could outperform next yearTrade Risk Report & Weekly Top Gainers Trade List - newser.com

Oct 03, 2025

Evaluating PTC Therapeutics Inc. with trendline analysisWeekly Stock Report & Low Risk High Win Rate Stock Picks - newser.com

Oct 03, 2025

Is PTC Therapeutics Inc. (BH3) stock among top earnings playsBear Alert & Low Risk High Reward Trade Ideas - newser.com

Oct 03, 2025

Will PTC Therapeutics Inc. (BH3) stock outperform energy sector in 20252025 Macro Impact & Consistent Income Trade Ideas - newser.com

Oct 03, 2025

Using AI based signals to follow PTC Therapeutics Inc.2025 Historical Comparison & Reliable Intraday Trade Plans - newser.com

Oct 03, 2025

Ptc Therapeutics stock hits 52-week high at 63.33 USD By Investing.com - Investing.com Nigeria

Oct 03, 2025

Oct 02, 2025

Ptc Therapeutics stock hits 52-week high at 63.33 USD - Investing.com India

Oct 02, 2025

Oct 01, 2025

19,475 Stock Options, 39,060 RSUs: PTC Therapeutics Awards Major Inducement Grants to New Employees - Stock Titan

Oct 01, 2025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Oct 01, 2025

Sep 30, 2025

PTC Therapeutics to Participate at Upcoming Investor Conferences - GuruFocus

Sep 30, 2025

PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Sep 30, 2025

Sep 29, 2025

Larimar Proceeding Toward Accelerated Approval Filing In Friedreich’s Ataxia - insights.citeline.com

Sep 29, 2025

PTC Therapeutics says Duchenne drug Translarna is no longer authorized in EU - MSN

Sep 29, 2025

How to build a custom watchlist for PTC Therapeutics Inc.Options Play & AI Powered Market Entry Strategies - newser.com

Sep 29, 2025

PTC Therapeutics (PTCT): Assessing Valuation After New Huntington’s Data Shifts Competitive Landscape and Investor Sentiment - Yahoo Finance

Sep 29, 2025

Sep 28, 2025

Is PTC Therapeutics Inc a good long term investmentShort-Term Trading Alerts & Small Investment Portfolio Growth - earlytimes.in

Sep 28, 2025

Sep 27, 2025

PTC Therapeutics Inc Stock Analysis and ForecastGlobal Market Influence & Market Crushing Stock Picks - earlytimes.in

Sep 27, 2025

Sep 26, 2025

Financiere des Professionnels Fonds d investissement inc. Makes New $284,000 Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat

Sep 22, 2025

Financiere des Professionnels Fonds d investissement inc. Buys Shares of 5,821 PTC Therapeutics, Inc. $PTCT - MarketBeat

Sep 22, 2025

CHMP maintains negative opinion on PTC Therapeutics' DMD treatment - MSN

Sep 22, 2025